All-In-One Malaria Cure Discovered By African Professor

All-In-One Malaria Cure Discovered By African Professor

By Shinji Tutoru

UNIVERSITY OF CAPE TOWN, RONDEBOSCH, SOUTH AFRICA. Researchers may have found a single-dose cure for all types of Malaria. They have been working on it for the past years and finally, there have been some developments. The cure comes in tablet form and it could be the answer to the growing cases of child deaths due to the deadly disease carried by mosquitoes.

Through the years, the Malaria parasite has grown stronger and more immune to the conventional Malaria treatments that we are getting from health centers. This super pill could actually cure and help millions of people around the world from the deadly Malaria diseases. At the same time, it will also help save a lot of money which is being allotted for the government’s health department.

This miracle cure in a pill was developed by Professor Kelly Chibale together with his team of dedicated researchers. For 18 months, they slowly developed the cure which has been proven to kill the resistant Malaria parasites in an instant. The drug has also been tested on animals which showed no side effects. Right now, there are several scheduled clinical tests for the end of 2013.

Another reason why this cure is considered as a medical breakthrough is because it is the first ever clinical molecule ever discovered by Africans outside Africa. It was discovered from a modern pharmaceutical industry drug discovery programme by the group of African researchers.

Invention Single-dose cure for all strains of malaria
Organization University of Cape Town, Rondebosch, South Africa
Researcher Prof. Kelly Chibale & Team
Field(s) Anti-malaria, Genetically Modified Mosquitoes, Malaria, Malaria Parasites, Mosquitoes
Further Information POPSCI

Never miss an insight

Get insights delivered right to your inbox

More of Our Insights & Work

Never miss an insight

Get insights delivered right to your inbox

You have successfully subscribed to our newsletter.

Too many subscribe attempts for this email address.

*